M. Skalland

Seattle Children's Hospital

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist”.

Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist

Journal of Clinical Investigation(2023)10.1172/jci167957

N/A

4.7DataRank · unranked

210 citations

Sarah J. Morgan, M. Skalland, Anh T. Vo, Jill M. Van Dalfsen, Sachinkumar B. Singh +9 more

Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI

Journal of Cystic Fibrosis(2022)10.1016/j.jcf.2022.10.003

N/A

4.1DataRank · unranked

125 citations

Phuong T. Vu, M. Skalland, Lucas R. Hoffman, Christopher E. Pope, Daniel Gelfond +16 more

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

The Lancet Respiratory Medicine(2022)10.1016/s2213-2600(22)00434-9

N/A

3.9DataRank · unranked

127 citations

Félix Ratjen, Renee Russell, Scott H. Donaldson, Kristin A. Riekert, Gregory S. Sawicki +91 more

The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis

Journal of Cystic Fibrosis(2021)10.1016/j.jcf.2021.02.012

N/A

0.670DataRank · unranked

10 citations

Sonya L. Heltshe, M. Skalland, Noah Lechtzin, Dave P. Nichols, Christopher H. Goss +1 more

Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study

Journal of Cystic Fibrosis(2021)10.1016/j.jcf.2021.01.011

N/A

0.483DataRank · unranked

24 citations

Michael W. Konstan, Donald R. VanDevanter, Steven M. Rowe, JP Clancy, Katherine Odem‐Davis +3 more

Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas

Journal of Cystic Fibrosis(2022)10.1016/j.jcf.2022.02.015

N/A

0DataRank · unranked

14 citations

M. Skalland, Scott D. Sagel, Bonnie W. Ramsey, Nicole Mayer-Hamblett, George Retsch‐Bogart +1 more

Antipseudomonal treatment decisions during CF exacerbation management

Journal of Cystic Fibrosis(2022)10.1016/j.jcf.2022.04.006

N/A

0DataRank · unranked

12 citations

Natalie E. West, Don B. Sanders, M. Skalland, Christopher H. Goss, Patrick A. Flume +2 more

Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation

Journal of Cystic Fibrosis(2021)10.1016/j.jcf.2021.11.009

N/A

0DataRank · unranked

19 citations

Umer Khan, Sonya L. Heltshe, M. Skalland, Natalie E. West, Donald R. VanDevanter +3 more